In a recent development, a medical device trade group has urged the U.S. Supreme Court to review a Federal Circuit decision concerning an intellectual property safe harbor provision. This appeal follows claims from Edwards Lifesciences, which argued that the circuit court’s decision improperly expanded the safe harbor meant for drug development, potentially allowing for avoidance of patent infringement. The trade group asserts that the Federal Circuit misinterpreted the provision, thus necessitating higher judicial review.
The implications of this request for Supreme Court intervention are significant for the pharmaceutical and medical device industries. The outcome could reshape the boundaries of the safe harbor, affecting the extent of patent infringement liabilities in drug and device development. For more details, you can read the article here.